(Hypertension. 1995;26:1134-1137.)
© 1995 American Heart Association, Inc.
Articles |
From the Department of Internal Medicine, Hypertension and Vascular Research Laboratories, University of Texas Medical Branch, Galveston.
Correspondence to Donna H. Wang, MD, The University of Texas Medical Branch, Department of Internal Medicine, Hypertension and Vascular Research Laboratories, 8.104 Medical Research Bldg, Galveston, TX 77555-1065. E-mail dwang%intmeds1@mhost.utmb.edu.
| Abstract |
|---|
|
|
|---|
Key Words: receptor, angiotensin II genes sodium kidney adrenal gland
| Introduction |
|---|
|
|
|---|
An important result of our previous work was that AT1A mRNA levels in the kidney are significantly increased by low dietary sodium intake,4 suggesting that expression of the AT1A receptor in the kidney is linked with salt and water homeostasis. Interestingly, sodium depletion, known to activate the renin-angiotensin system, also increases AT1A mRNA levels in the adrenal gland.5 In contrast, adrenal AT1A mRNA levels were not altered in two-kidney, one clip hypertensive rats in which circulating PRA was also elevated.5 These experiments raise questions regarding the mechanism by which low dietary sodium regulates AT1A mRNA levels in both the kidney and adrenal gland. The present study was therefore designed to test the hypothesis that sodium deficiencyinduced modulation of AT1A mRNA in both the kidney and adrenal gland is mediated by activation of the AT1 receptor.
| Methods |
|---|
|
|
|---|
Plasma Renin Activity
At the end of the 2-week diet treatments, all the rats were
anesthetized with a single injection of 100 mg/kg IP thiopental
sodium. The right carotid artery was catheterized for the
measurement of MAP with a Statham 231D pressure transducer (Gould
Inc) coupled to a Gould 2400S recorder (Gould Inc). The rats were
heparinized (1 U/g), and samples of plasma (3 mL) were collected from
the carotid artery and placed in chilled EDTA tubes. PRA was determined
using a commercially available radioimmunoassay kit for angiotensin I
(Incstar Co).
Tissue Preparation
To obtain tissue for Northern blot analysis, a midline
incision in the abdomen was performed, and the left kidney and both
adrenal glands were promptly removed, weighed, frozen in liquid
nitrogen, and processed for RNA extraction.
cDNA Probes
Preparation of AT1A cDNA probes has been
described in our recent publication.4 Briefly, to make
AT1A-specific cDNA probes, the PCR method was used to
amplify AT1A cDNA (a generous gift of Dr Tadashi Inagami,
Vanderbilt University School of Medicine, Nashville).6 The
primers used were 5'-sense primer=5'-TGGCTTACGACCAAAGGACCA-3'
(+1142 to +1162), 3'-antisense primer=5'-CAAAGGGAGACTGATGAGATTG-3'
(+1355 to +1377). These primers span a noncoding region where
AT1A and AT1B cDNAs exhibit a minimum sequence
homology. The reaction profile included 30 cycles of denaturation at
95°C for 45 seconds, annealing at 55°C for 60 seconds, and
polymerization at 72°C for 90 seconds. The DNA sequence of PCR
product was verified by using a USB sequencing kit (United States
Biochemical Co). A 235-bp PCR product was inserted into
EcoRV site of pBluescript KS(+) vector, and the fragment
that was cleaved with EcoRI and HindIII was used
as a template for making AT1A cDNA probes. The
AT1A cDNA probes were labeled with [32P]dCTP
using a Multiprime DNA labeling system (Amersham Co) to a specific
activity of 3x108 CPM/µg. The labeled probes were
separated from unincorporated nucleotide using Mini-Spin
G-50 DNA purification spin columns (Worthington Biochemical, Co).
RNA Extraction and Northern Blots
Total RNA of kidney and adrenal gland was extracted using
the guanidine thiocyanatephenolchloroform extraction
protocol.7 Electrophoresis of 30 µg denatured RNA from
each preparation was carried out in a 1% agarose gel containing 2.2
mol/L formaldehyde. RNA was transferred to a positively charged nylon
membrane (Fisher Co). The membrane was baked at 80°C for 2 hours in a
vacuum oven (Fisher Co) and prehybridized for 5 hours at 42°C in
hybridization buffer (50% deionized formamide, 5x Denhardt's
solution, 5x SSC, 0.5% sodium dodecyl sulfate, and 200
µg/mL of denatured salmon sperm DNA). The membrane was hybridized
with the 32P-labeled probes in the hybridization buffer for
18 to 20 hours at 42°C; then it was washed successively in 2x, 1x,
and 0.5x SSC (two times, 10 minutes each) containing 0.1% sodium
dodecyl sulfate. Stringencies of washes were 65°C. Blots were
exposed to XAR-5 x-ray film (Eastman Kodak Co) with intensifying
screen. To correct the differences in RNA loading, Northern blots were
incubated at 90°C for 10 minutes in 20 mmol/L Tris-HCl (pH 8.0) to
strip off the cDNA probes and rehybridized with
[32P]-labeled GAPDH cDNA probes.
Autoradiographic signals were scanned with a laser
densitometer (Ultrascan XL, Pharmacia). Relative gene expression was
factored for GAPDH mRNA.
Statistical Analysis
Results were expressed as mean±SEM. The data were
analyzed by one-way ANOVA followed by the Tukey-Kramer
multiple comparison test. Differences were considered statistically
significant at the P<.05 level.
| Results |
|---|
|
|
|---|
|
|
Renal AT1A mRNA content was determined by Northern blot analysis in each of the four groups of rats (Fig 2A). Blots were then stripped and rehybridized to GAPDH cDNA probes. Densitometric analysis (Fig 2B) indicated that the ratio of AT1A mRNA to GAPDH mRNA was significantly elevated by DuP treatment (1.17±0.10), sodium restriction (1.12±0.03), or the combination of the two (0.96±0.06) compared with controls (0.66±0.04, P<.05).
|
Fig 3A shows adrenal AT1A mRNA levels determined by Northern blot analysis in each of the four groups of rats. Blots were then stripped and rehybridized to GAPDH cDNA probes. Densitometric analysis (Fig 3B) indicated that the ratio of AT1A mRNA to GAPDH mRNA was significantly increased by sodium restriction (1.58±0.09, P<.05) compared with controls (0.58±0.05), DuP treatment (0.68±0.03), and the combination of the two (0.69±0.09).
|
| Discussion |
|---|
|
|
|---|
It has been demonstrated that AT1 is the predominant receptor in the rat and human kidney and seems to account for all the known physiological consequences of Ang II binding.1 2 3 Recently, we used probes from the 3'-untranslated regions of the cDNAs encoding the AT1A and AT1B receptor subtypes, which allowed us to distinguish between mRNA expression for AT1A and AT1B, and found that AT1A is the predominant subtype of the AT1 receptor in the kidney. This conclusion is based on the fact that AT1A mRNA was readily detected with Northern blot analysis, whereas AT1B could be detected only with the more sensitive in situ hybridization.4 Our findings are supported by that of Llorens-Cortes et al,5 who used reverse transcription and PCR amplification and showed that, if expressed as a percentage of total AT1A+AT1B receptor mRNA content, AT1A receptor mRNA content was 73% in the kidney.5 Although no pharmacological approaches are available for distinguishing between AT1A and AT1B, the predominant distribution of AT1A mRNA in the kidney suggests that most physiological consequences of Ang II binding may be mediated by the AT1A receptor subtype. A cautionary note: all of this work is based on the study of message levels and not receptor protein number. Since there are examples of high levels of protein with relatively rare message copy, one cannot rule out the possibility that AT1B receptors are present in the kidney.
Consistent with our previous finding,4 low sodium intake upregulates AT1A receptor mRNA expression. Similarly, sodium depletion upregulates the AT1A receptor mRNA expression in the adrenal gland, suggesting that low sodiuminduced upregulation of AT1A is not kidney specific. The mechanism for this upregulation is unclear. Given our understanding of the renin-angiotensin system, increased PRA induced by sodium depletion should result in elevated circulating and/or local Ang II levels. Thus, Ang II could modulate AT1A gene expression by a positive feedback mechanism through the activation of the AT1 receptor. Indeed, this mechanism seems to account for low sodiuminduced upregulation of AT1A mRNA in the adrenal gland because DuP fully blocked the response. In contrast, renal AT1A mRNA levels in rats fed a low sodium diet remained elevated in the presence of DuP. There are several potential explanations. One is that DuP has a direct effect on certain specific renal cells to enhance AT1A mRNA expression. In support of this, we dissected the kidney into the cortex and medulla and found that, while low sodium intake selectively enhances AT1 mRNA expression in the medulla, DuP significantly increases AT1 mRNA expression in the cortex only (unpublished data). The second possibility is that, in contrast with the adrenal gland, there is a very low abundance of the AT2 receptor in the kidney. It is possible that excess Ang II induced by DuP treatment binds to the AT2 receptor and has an as yet unknown effect on the regulation of the AT1A gene in the kidney and adrenal gland. This hypothesis could be tested by the simultaneous blockade of the AT1 and AT2 receptors. A third possibility is that elevated Ang II may have negative feedback regulation on AT1A gene expression in the kidney8 but not the adrenal gland, and blockade of the AT1 receptor by DuP eliminates a negative feedback signal and increases renal AT1A mRNA expression. This possibility could be tested by giving Ang II directly to the rats. A fourth consideration is that previous studies on the genomic structure and the promoter region sequence of AT1A have shown that several glucocorticoid-responsive elements exist in the 5'-regulatory region and account for stimulation by aldosterone.9 10 It is possible, therefore, that the release of aldosterone induced by low sodium intake causes the increase in AT1A mRNA expression in both kidney and adrenal gland. Because it has been demonstrated that aldosterone release is AT1 dependent,11 the differences in AT1A mRNA levels between the kidney and adrenal gland after DuP treatment may reflect different responses of the adrenal and kidney tissues to the altered aldosterone concentration. This mechanism could be tested by preventing the release of aldosterone during sodium depletion.
In conclusion, we have demonstrated that sodium depletion increases AT1A mRNA levels in both kidney and adrenal gland. Different mechanisms of regulation of AT1A by sodium exist in these tissues. While low sodiuminduced upregulation of AT1A in the adrenal gland is AT1 dependent, a non-AT1dependent mechanism is operant in the kidney. We propose that the existence of distinct regulatory mechanisms will provide an opportunity for selective manipulation of Ang II receptors in different tissues. This could provide a means for differentially altering ion homeostasis, BP, or tissue growth.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received June 18, 1995; first decision August 18, 1995; accepted September 10, 1995.
| References |
|---|
|
|
|---|
2. De Gaspero M, Whitebread S, Mele M, Motani AS, Whitcombe PJ, Ramjoue HP, Kamber B. Biochemical characterization of two angiotensin II receptor subtypes in the rat. J Cardiovasc Pharmacol. 1990;16:S31-S35.
3.
Sechi LA, Grady EF, Griffin CA, Kalinyak JE,
Schambelan M. Distribution of angiotensin II
subtypes in rat and human kidney. Am J Physiol. 1992;262:F236-F240.
4. Du Y, Yao A, Guo DF, Inagami T, Wang DH. Differential regulation of angiotensin II receptor subtypes in rat kidney by low dietary sodium. Hypertension. 1995;25[pt 2]:872-877.
5.
Llorens-Cortes C, Greenberg B, Huang HM, Corvol P.
Tissular expression and regulation of type 1
angiotensin II receptor subtypes by quantitative reverse
transcriptase-polymerase chain reaction analysis.
Hypertension. 1994;24:538-548.
6. Iwai N, Yamano S, Chaki S, Konishi F, Bardhan S, Tibbetts C, Sasaki K, Hasegawa M, Matsuda Y, Inagami T. Rat angiotensin II receptor: cDNA sequence and regulation of the gene regulation. Biochem Biophys Res Commun. 1991;177:299-304. [Medline] [Order article via Infotrieve]
7. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159. [Medline] [Order article via Infotrieve]
8.
Tufro-McReddie A, Chevalier RL, Everett AD, Gomez RA.
Decreased perfusion pressure modulates renin and Ang II type 1
receptor gene expression in rat kidney. Am J
Physiol. 1993;264:R696-R702.
9. Makita N, Fukunaga M, Iwai N. Two distinct pathways in the down-regulation of type-1 angiotensin II receptor gene in rat aortic smooth muscle cells. Circulation. 1992;86(suppl I):I-90. Abstract.
10.
Takeuchi K, Alexander W, Nakamura Y, Tsujino T, Murphy
TJ. Molecular structure and transcriptional function of the rat
vascular AT1A angiotensin receptor gene.
Circ Res. 1993;73:612-621.
11. Aguilera G. Role of angiotensin II receptor subtypes on the regulation of aldosterone secretion in the adrenal glomerulosa zone in the rat. Mol Cell Endocrinol. 1992;90:53-60.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
J. M. Perez-Rojas, S. Derive, J. A. Blanco, C. Cruz, L. M. de la Maza, G. Gamba, and N. A. Bobadilla Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity Am J Physiol Renal Physiol, November 1, 2005; 289(5): F1020 - F1030. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Imig, G. L. Navar, L.-X. Zou, K. C. O'Reilly, P. L. Allen, J. H. Kaysen, T. G. Hammond, and L. G. Navar Renal endosomes contain angiotensin peptides, converting enzyme, and AT1A receptors Am J Physiol Renal Physiol, August 1, 1999; 277(2): F303 - F311. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Wang, A. Yao, H. Zhao, and D. J. DiPette Distinct Mechanisms of Modulation of Angiotensin II Type I Receptor Gene Expression in Heart and Aorta Hypertension, May 1, 1997; 29(5): 1104 - 1108. [Abstract] [Full Text] |
||||
![]() |
F. Elijovich, H.-W. Zhao, C. L. Laffer, Y. Du, D. J. DiPette, T. Inagami, and D. H. Wang Regulation of Growth of the Adrenal Gland in DOC-Salt Hypertension: Role of Angiotensin II Receptor Subtypes Hypertension, January 1, 1997; 29(1): 408 - 413. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |